Drugs / EBRIBAFUSP ALFA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06419205 | Jul 2026 → Feb 2028 expected | IgA glomerulonephritis, complement 3 glomerulopathy, lupus nephritis | Akebia Therapeutics | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-02-21 | Q32 Bio Inc. | Results Q32 Bio Announces Publication of Preclinical Data in Molecular Therapy Demonstrating the Therapeutic Potential of Tissue-Targeted Complement Inhibitor ADX-097 for Complement-Mediated Diseases q32bio.com ↗
Q32 Bio Inc., a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the publication of preclinical data in Molecular Therapy that further validates the therapeutic potential of ADX-097, a tissue-targeted complement inhibitor. |
| 2022-06-23 | Q32 Bio Inc. | Results Q32 Bio Presents New Preclinical Data at the International Society of Nephrology Frontiers Meeting Demonstrating the Therapeutic Potential of ADX-097 q32bio.com ↗
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that the Company presented new preclinical data demonstrating the therapeutic potential of ADX-097, Q32's lead program for innate immunity. |
| 2021-12-13 | Q32 Bio Inc. | Results Q32 Bio Presents Preclinical Data Highlighting the Design and Characterization of Lead Program for Innate Immunity, ADX-097, at the 28th International Complement Virtual Workshop 2021 q32bio.com ↗
Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced preclinical data for the Company's lead program for innate immunity, ADX-097. |
| 2021-11-08 | Q32 Bio Inc. | Results Q32 Bio Presents Preclinical Data Supporting Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021 q32bio.com ↗
These data validate the mechanism of action of ADX-097, a first-in-class fusion protein, and demonstrate the ability to potently inhibit disease-causing complement activation in a targeted manner while avoiding systemic complement inhibition. |
All press releases naming this drug 8 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBRIBAFUSP ALFA | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068113 ↗ |
| Known as | ADX-097 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06419205 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL6068113 ↗ |
| Route | Subcutaneous | “ADX-097 Administered Subcutaneously” NCT06419205 ↗ |